348 related articles for article (PubMed ID: 29558390)
1. PPARβ/δ: A Key Therapeutic Target in Metabolic Disorders.
Palomer X; Barroso E; Pizarro-Delgado J; Peña L; Botteri G; Zarei M; Aguilar D; Montori-Grau M; Vázquez-Carrera M
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29558390
[TBL] [Abstract][Full Text] [Related]
2. Peroxisome proliferator-activated receptor beta/delta as a therapeutic target for metabolic diseases.
Bedu E; Wahli W; Desvergne B
Expert Opin Ther Targets; 2005 Aug; 9(4):861-73. PubMed ID: 16083348
[TBL] [Abstract][Full Text] [Related]
3. Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) attenuates carbon tetrachloride hepatotoxicity by downregulating proinflammatory gene expression.
Shan W; Palkar PS; Murray IA; McDevitt EI; Kennett MJ; Kang BH; Isom HC; Perdew GH; Gonzalez FJ; Peters JM
Toxicol Sci; 2008 Oct; 105(2):418-28. PubMed ID: 18622026
[TBL] [Abstract][Full Text] [Related]
4. GQ-130, a novel analogue of thiazolidinedione, improves obesity-induced metabolic alterations in rats: Evidence for the involvement of PPARβ/δ pathway.
Silva OA; Ribeiro-Filho HV; Avelino TM; Tittanegro TH; Figueira ACM; Rabelo LA; Pitta IDR; Lahlou S; Duarte GP
Clin Exp Pharmacol Physiol; 2020 May; 47(5):798-808. PubMed ID: 31909493
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological PPARβ/δ activation upregulates VLDLR in hepatocytes.
Zarei M; Barroso E; Palomer X; Escolà-Gil JC; Cedó L; Wahli W; Vázquez-Carrera M
Clin Investig Arterioscler; 2019; 31(3):111-118. PubMed ID: 30987865
[TBL] [Abstract][Full Text] [Related]
6. Targeting PPARβ/δ for the treatment of type 2 diabetes mellitus.
Salvadó L; Serrano-Marco L; Barroso E; Palomer X; Vázquez-Carrera M
Expert Opin Ther Targets; 2012 Feb; 16(2):209-23. PubMed ID: 22280315
[TBL] [Abstract][Full Text] [Related]
7. Regulation of Cytochrome P450 2B10 (CYP2B10) Expression in Liver by Peroxisome Proliferator-activated Receptor-β/δ Modulation of SP1 Promoter Occupancy.
Koga T; Yao PL; Goudarzi M; Murray IA; Balandaram G; Gonzalez FJ; Perdew GH; Fornace AJ; Peters JM
J Biol Chem; 2016 Nov; 291(48):25255-25263. PubMed ID: 27765815
[TBL] [Abstract][Full Text] [Related]
8. Activation of peroxisome proliferator-activated receptor beta/delta induces lung cancer growth via peroxisome proliferator-activated receptor coactivator gamma-1alpha.
Han S; Ritzenthaler JD; Sun X; Zheng Y; Roman J
Am J Respir Cell Mol Biol; 2009 Mar; 40(3):325-31. PubMed ID: 18776129
[TBL] [Abstract][Full Text] [Related]
9. Peroxisome proliferator-activated receptor (PPAR) beta/delta: a new potential therapeutic target for the treatment of metabolic syndrome.
Coll T; Rodrïguez-Calvo R; Barroso E; Serrano L; Eyre E; Palomer X; Vázquez-Carrera M
Curr Mol Pharmacol; 2009 Jan; 2(1):46-55. PubMed ID: 20021445
[TBL] [Abstract][Full Text] [Related]
10. Establishing the Role of PPARβ/δ in Carcinogenesis.
Peters JM; Gonzalez FJ; Müller R
Trends Endocrinol Metab; 2015 Nov; 26(11):595-607. PubMed ID: 26490384
[TBL] [Abstract][Full Text] [Related]
11. Harnessing the benefits of PPARβ/δ agonists.
Mackenzie LS; Lione L
Life Sci; 2013 Dec; 93(25-26):963-7. PubMed ID: 24184294
[TBL] [Abstract][Full Text] [Related]
12. The role of PPARβ/δ in the management of metabolic syndrome and its associated cardiovascular complications.
Benetti E; Patel NS; Collino M
Endocr Metab Immune Disord Drug Targets; 2011 Dec; 11(4):273-84. PubMed ID: 21696362
[TBL] [Abstract][Full Text] [Related]
13. Insights into the Role of PPARβ/δ in NAFLD.
Chen J; Montagner A; Tan NS; Wahli W
Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29954129
[TBL] [Abstract][Full Text] [Related]
14. Ligand-mediated regulation of peroxisome proliferator-activated receptor (PPAR) beta/delta: a comparative analysis of PPAR-selective agonists and all-trans retinoic acid.
Rieck M; Meissner W; Ries S; Müller-Brüsselbach S; Müller R
Mol Pharmacol; 2008 Nov; 74(5):1269-77. PubMed ID: 18701617
[TBL] [Abstract][Full Text] [Related]
15. Hepatic regulation of VLDL receptor by PPARβ/δ and FGF21 modulates non-alcoholic fatty liver disease.
Zarei M; Barroso E; Palomer X; Dai J; Rada P; Quesada-López T; Escolà-Gil JC; Cedó L; Zali MR; Molaei M; Dabiri R; Vázquez S; Pujol E; Valverde ÁM; Villarroya F; Liu Y; Wahli W; Vázquez-Carrera M
Mol Metab; 2018 Feb; 8():117-131. PubMed ID: 29289645
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptor (PPAR)-gamma positively controls and PPARalpha negatively controls cyclooxygenase-2 expression in rat brain astrocytes through a convergence on PPARbeta/delta via mutual control of PPAR expression levels.
Aleshin S; Grabeklis S; Hanck T; Sergeeva M; Reiser G
Mol Pharmacol; 2009 Aug; 76(2):414-24. PubMed ID: 19483106
[TBL] [Abstract][Full Text] [Related]
17. PPARβ/δ-ANGPTL4 axis mediates the promotion of mono-2-ethylhexyl phthalic acid on MYCN-amplified neuroblastoma development.
Liu Y; Hamid N; Manzoor R; Zhang BF; Liao YL; Wang JX; Pei DS
Sci Total Environ; 2024 Feb; 912():168949. PubMed ID: 38042186
[TBL] [Abstract][Full Text] [Related]
18. The PPARβ/δ-AMPK Connection in the Treatment of Insulin Resistance.
Aguilar-Recarte D; Palomer X; Wahli W; Vázquez-Carrera M
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445261
[TBL] [Abstract][Full Text] [Related]
19. Ligand activation of peroxisome proliferator-activated receptor-beta/delta and inhibition of cyclooxygenase-2 enhances inhibition of skin tumorigenesis.
Bility MT; Zhu B; Kang BH; Gonzalez FJ; Peters JM
Toxicol Sci; 2010 Jan; 113(1):27-36. PubMed ID: 19748995
[TBL] [Abstract][Full Text] [Related]
20. Human Endometrial Stromal Cell Differentiation is Stimulated by PPARβ/δ Activation: New Targets for Infertility?
Yu J; Berga SL; Zou W; Rajakumar A; Man M; Sidell N; Taylor RN
J Clin Endocrinol Metab; 2020 Sep; 105(9):2983-95. PubMed ID: 32594141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
